Work

Abstract LB-092: TAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-lb-092

Authors: Lipika Goyal, Leah Y. Liu, Jochen K. Lennerz, James J. Harding, Jerry Huang, Robert Winkler, Hirai Hiroshi, David T. Ting, Dejan Juric, Ryan B. Corcoran, Nabeel El-Bardeesy, Andrew X. Zhu

Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Taiho Oncology (United States), Taiho Pharmaceutical (Japan)

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2886115774

Cites:

Cited by: 4

Related to: 10